Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Morgan Stanley analyst Craig Hettenbach maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target ...

What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.

While Hims offers more options for sexual health ... But how do these two companies’ products and services compare? Read on for our full review and how to decide which one may work best for ...

Hims & Hers began offering compounded GLP-1 products in late May 2024. While that's helped revenue growth reaccelerate, management noted that subscriptions still grew 40% year over year in Q3 of ...

Hims & Hers Health has seen its stock drop 21% over the past month. The pullback is driven by regulatory updates from the FDA regarding tirzepatide injection shortages. Get Real-Time News and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

BTIG initiated coverage of Hims & Hers with a Buy rating and $35 price target The firm says its likes Hims & Hers because of its ...

HIMS) is rewriting the telehealth playbook while its competitors scramble. With a 200% YTD surge, the company's diversified approachcombining virtual consultations, over-the-counter products, and ...